EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis

Tânia Rodrigues, Joana Albuquerque, Joana Cardoso, Ivo Sousa-Ferreira, João Paulo Martins, José Luís Passos Coelho

Cancer Treatment and Research Communications · 2026

DOI: 10.1016/j.ctarc.2025.101091 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Tânia Rodrigues und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hospital da Luz Lisboa, Lisboa, Portugal; Nova Medical School, Universidade Nova de Lisboa, Lisboa, Portugal; Católica Medica…. Hauptthemen laut MEDLINE: Smad4 Protein, Pancreatic Neoplasms, Mutation, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regional Agency for the Development of Research Technology and Innovation, Fundação para a Ciência e a Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The prognostic value of SMAD4 in pancreatic cancer has been evaluated in several studies. However, the conclusions remain controversial. Therefore, we aimed to evaluate the prognostic value of the SMAD4 gene in pancreatic cancer to aid in the design of therapeutic strategies. METHODS: This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria and the proposed methodology was registered on PROSPERO. An electronic search was made in MEDLINE (via PubMed), Web of Science and Google Scholar to identify all relevant studies. Eligible studies were those written in English including patients with Pancreatic Ductal Adenocarcinoma (PDAC), who underwent pancreatic surgery with curative intent and provided data on SMAD4 gene status or SMAD4 protein expression and its association to prognosis, measured by overall survival (OS). The effect measure of interest was the hazard ratio (HR) for OS between PDAC with or without SMDA4 mutations. RESULTS: A total of 24 studies on SMAD4, with 4340 samples, were included in this systematic review and meta-analysis. Our pooled results demonstrated that patients with tumours with SMAD4 alteration had significantly worse prognosis for OS (HR= 1.43, 95% CI = 1.17-1.76, p-value = 0.002). CONCLUSION: This systematic review and meta-analysis support the use of driver mutations in the SMAD4 gene as a prognostic marker for pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smad4 ProteinPancreatic NeoplasmsMutationCarcinoma, Pancreatic DuctalBiomarkers, TumorHumansPrognosis

Stichwörter der Autor:innen

ImmunohistochemistryMutationPancreatic cancer (PDAC)PrognosticSMAD4 geneSMAD4 protein

Substanzen

Smad4 ProteinSMAD4 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, Hospital da Luz Lisboa, Lisboa, Portugal; Nova Medical School, Universidade Nova de Lisboa, Lisboa, Portugal; Católica Medical School, Universidade Católica Portuguesa, Sintra, Portugal. Electron…
  • Department of Oncology, Hospital da Luz Lisboa, Lisboa, Portugal; Católica Medical School, Universidade Católica Portuguesa, Sintra, Portugal.
  • Ophiomics - Precision Medicine, Lisbon, Portugal.
  • CEAUL - Centro de Estatística e Aplicações, Faculdade de Ciências, Universidade de Lisboa, Portugal; Departamento de Matemática, Faculdade de Ciências Exatas e da Engenharia, Universidade da Madeira, Portugal.
  • Escola Superior de Saúde, Instituto Politécnico do Porto, Porto, Portugal; CEAUL - Centro de Estatística e Aplicações, Faculdade de Ciências, Universidade de Lisboa, Portugal; Centre for Health Studies and Research of U…
  • Department of Oncology, Hospital da Luz Lisboa, Lisboa, Portugal; Nova Medical School, Universidade Nova de Lisboa, Lisboa, Portugal; Católica Medical School, Universidade Católica Portuguesa, Sintra, Portugal.

Förderung

  • Regional Agency for the Development of Research Technology and Innovation
  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

Rodrigues, T., Albuquerque, J., Cardoso, J., Sousa-Ferreira, I., Martins, J. P., & Coelho, J. L. P. (2026). Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.101091

Vancouver

Rodrigues T, Albuquerque J, Cardoso J, Sousa-Ferreira I, Martins JP, Coelho JLP. Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2025.101091

BibTeX
@article{Rodrigues2026,
  author = {Rodrigues, Tânia and Albuquerque, Joana and Cardoso, Joana and Sousa-Ferreira, Ivo and Martins, João Paulo and Coelho, José Luís Passos},
  title = {Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  doi = {10.1016/j.ctarc.2025.101091}
}
Kostenlos starten →